搜索
Zenas Biopharma Inc
ZBIO添加自选
19.260USD
-0.670-3.36%
交易中 （美东）报价延迟15分钟
1.05B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.36%
5天
-7.54%
1月
-8.46%
6月
-45.99%
今年开始到现在
-46.96%
1年
+111.88%
TradingKey Zenas Biopharma Inc股票评分
单位: USD 更新时间: 2026-05-13操作建议
Zenas Biopharma Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名66/383位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价42.00。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Zenas Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Zenas Biopharma Inc亮点
亮点风险
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
业绩增长期
公司处于发展阶段，最新年度总收入10.00M美元
利润高增长
公司净利润处于行业前列，最新年度总收入10.00M美元
估值合理
公司最新PE估值-2.36，处于3年历史合理位
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值345.02K
分析师目标
根据
8
位分析师
强力买入
评级
42.000
目标均价
+105.88%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Zenas Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Zenas Biopharma Inc简介
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
公司代码ZBIO
公司Zenas Biopharma Inc
CEOMoulder (Leon O)
网址https://zenasbio.com/
相关品种
